Nurix Therapeutics Inc (NRIX) valuation
Nurix Therapeutics P/E ratio history
Nurix Therapeutics trades at 11.7 times its earnings over the last twelve months.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Nov 30, 2025 | $17.68 | -$3.05 | n/m |
| Nov 30, 2024 | $22.11 | -$2.88 | n/m |
| Nov 30, 2023 | $6.22 | -$2.65 | n/m |
| Nov 30, 2022 | $12.39 | -$3.71 | n/m |
| Nov 30, 2021 | $28.82 | -$2.73 | n/m |
| Nov 30, 2020 | $42.62 | — | n/m |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Nurix Therapeutics valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Nurix TherapeuticsNRIX | $2.78B | 11.7 | — | 4.0 |
| Beam TherapeuticsBEAM | $2.80B | — | — | 18.0 |
| Dyne TherapeuticsDYN | $2.76B | — | — | — |
| Ideaya BiosciencesIDYA | $2.81B | — | — | 12.0 |
| Privia Health GroupPRVA | $2.71B | 97.6 | 22.0 | 1.2 |
| Aveanna HealthcareAVAH | $2.87B | 10.4 | 15.2 | 1.1 |
| Enliven TherapeuticsELVN | $2.69B | — | — | — |
| Mbx BiosciencesMBX | $2.66B | — | — | — |
| AxogenAXGN | $2.65B | — | 73.6 | 9.9 |
| Peer median | 54.0 | 22.0 | 9.9 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: NRIX financials · NRIX returns
No forecast, no recommendation. This page describes Nurix Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.